Evaluation of an artificial intelligence-based clinical trial matching system in Chinese patients with hepatocellular carcinoma: a retrospective study

Table 1 Part of the patient attributes derived from CTMS

Attribute	No.	%
Age ≥ 18 years	1,048	99.5
Diagnosis
HCC	889	84.4
Non-HCC	164	15.6
Tumor status
BCLC B or C stage	686	65.1
Progressed and measurable lesions^a	228	21.7
Diffused or massive intrahepatic lesions	50	4.7
Diameter > 3 cm	553	52.5
Tumor adjacent to main vessels or gallbladder	64	6.1
Tumor thrombosis in main trunk of PV or in IVC	150	14.2
CNS metastases	12	1.1
ECOG-PS > 2	54	5.1
Child-Pugh ≥ 10	44	4.2
Large volume of ascites	51	4.8
Serious non-healing wound or fracture	2	0.2
Laboratory results
HBV-DNA > 2,000 IU/mL	70	6.6
ALT or AST > 5 ULN	290	27.5
Medical history
Current participation in clinical trials	84	8.0
Prior systemic anti-tumor treatments	493	46.8
HE	41	3.9
AIDS	6	0.6
Major cardiovascular diseases	11	1.0
Immune diseases underwent steroid treatment	16	1.5
Tuberculosis	20	1.9
Transplantation	10	0.9

^aNote: the definition of progressed and measurable lesion was consistent with the Response Evaluation Criteria in Solid Tumours (version 1.1). Abbreviations: HCC, hepatocellular carcinoma; BCLC, Barcelona Clinic Liver Cancer; PV, portal vein; IVC, inferior vena cava; CNS, central nervous system; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; HBV, hepatitis B virus; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ULN, upper limit of normal; AIDS, acquired immune deficiency syndrome; and HE, hepatic encephalopathy

ISSN: 1471-2407